News

During a Medical Crossfire at the 21st Annual International Lung Cancer Congress, Paul A. Bunn, Jr, MD, debated with Karen L. Reckamp, MD, MS, about frontline single-agent immune checkpoint inhibitors versus combined chemotherapy and immunotherapy for the treatment of patients with advanced NSCLC.

Targeted Oncology reviews trending news online for the week of October 16, 2020, including updates in oncology.

Patients with relapsed or refractory diffuse large B-cell lymphoma who have not found success in 2 or more lines of therapy face stiff odds, but new data suggest polatuzumab vedotin–based therapies may help improve outcomes.

An Orphan Drug Designation had been granted by the FDA to the CD40 antagonistic monoclonal antibody, APX005M for the treatment esophageal and gastroesophageal junction cancer, as well as for the treatment of patients with pancreatic cancer.

A significant reduction in the risk of death was observed with the addition of sipuleucel-T to either abiraterone acetate or enzalutamide as treatment of patients with metastatic castration-resistant prostate cancer in a real-world analysis.

The primary end point of prolonged progression-free survival in the phase 3 CHRONOS-3 study was met with copanlisib in combination with rituximab as treatment of patients with indolent non-Hodgkin lymphoma.

Uday R. Popat, MD, discusses the role of JAK inhibitors in patients with myeloproliferative neoplasms.

The FDA granted approval to the immune checkpoint inhibitor pembrolizumab as treatment of patients with relapsed or refractory classic Hodgkin lymphoma.

The first CD19/22-directed dual targeting CAR T cell AUTO3 demonstrated a tolerable and best-in-class safety profile as treatment of patients with relapsed/refractory diffuse large B-cell lymphoma.

The FDA granted a Fast Track designation to the novel agent PC14586 for the treatment of patients with locally advanced or metastatic solid tumors that harbor a P53 Y220C mutation.

Across subsets of patients with thyroid cancer, an interesting collection of research was shared with oncologists during the 2020 European Society of Medical Oncology Virtual Congress, demonstrating improvement in outcomes for patients with thyroid cancers with newer and established approved regimens.

Tazemetostat as a single agent demonstrated clinically meaningful durable responses as treatment of patients with heavily pretreated relapsed/refractory follicular lymphoma.

In an interview with Targeted Oncology, Rana R. McKay, MD, discussed the findings from the CheckMate-9ER study of nivolumab plus cabozantinib in patients with advanced or metastatic renal cell carcinoma who had not been previously treated.

The FDA has accepted an investigational New Drug application for the investigational CDK2/4/6 inhibitor NUV-422 for the treatment of patients with high-grade gliomas.

A number of targeted agents have been approved in the setting of metastatic breast cancer, which has allowed for more personalized treatment approaches and underscores the importance of genomic testing.

In an interview with Targeted Oncology, Lori J. Wirth, MD, discussed the findings from an analysis of the patient-reported outcomes observed in the LIBRETTO-001 study of selpercatinib in patients with RET-driven thyroid cancers.

Natalie S. Callander, MD, discusses the role of CAR T-cell therapy as treatment of patients with multiple myeloma.

Enfortumab vedotin-ejfv induced durable responses as treatment of patients with locally advanced or metastatic urothelial cancer who have previously received immunotherapy but not a prior platinum-containing chemotherapy and are not eligible for cisplatin.

Omidubicel as treatment of patients with high-risk hematologic malignancies induced rapid platelet engraftment and a reduction in the number of infections and hospitalizations, meeting all 3 secondary end points of a phase 3 clinical trial.

During a Targeted Oncology Case Based Peer Perspectives event, Sandy Ting Liu, MD, discussed the case of a62-year-old male patient with bladder cancer.

Breast cancer data reported during the 2020 European Society Medical Oncology Virtual Congress revealed major advances in the treatment paradigm. The agents included in these trials challenged that standard-of-care.

The creation of the CRISPR-Cas9, a novel gene-editing technology used in oncology and other areas of scientific research was the antecedent for Emmanuelle Charpentier, PhD, and Jennifer A. Doudna, PhD, being awarded the 2020 Nobel Prize in Chemistry.

Targeted Oncology reviews trending news online for the week of October 9, 2020, including updates in oncology and new information regarding COVID-19.

Palbociclib in combination with standard endocrine therapy did not improve invasive disease-free survival in patients with hormone receptor-positive, HER2-negative early breast cancer who have residual invasive disease after completing neoadjuvant chemotherapy, missing the primary end point of the phase 3 PENELOPE-B trial.

Multiple agents are now challenging chemotherapy as the golden standard in the front-line setting of advanced non–small cell lung cancer.

Obinutuzumab with dexamethasone plus high-dose cytarabine and cisplatin generated good activity for inducing bone marrow minimal residual disease negativity in patients with mantle cell lymphoma who are eligible for transplant.

The FDA issued a draft guidance that encourages the inclusion of premenopausal women with breast cancer in clinical trials, which will in order tohelp researchers determine the efficacy of a hormonal drug or biological products for this population along with others.

During a Targeted Oncology Case Based Peer Perspective event, Usama Gergis, MD, MBA, and Scott D. Rowley, MD, reviewed the case of a 35-year-old woman with moderate chronic graft-versus-host disease.

In an interview with Targeted Oncology, David J. Pinato, MD, PhD, reviewed how the treatment landscape of hepatocellular carcinoma has evolved over the years and the challenges that clinicians and researchers currently face in the field.

The combination of nivolumab plus chemotherapy induced a statistically significant improvement in pathologic complete response as neoadjuvant treatment of patients with resectable non–small cell lung cancer.